On May 18, 2020 Ryvu Therapeutics (WSE: RVU), a clinical stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, reported that it will present data from its multiple oncology programs at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II taking place June 22 to June 24, 2020 (Press release, Ryvu Therapeutics, MAY 18, 2020, View Source [SID1234558263]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data presented will include results from the small-molecule STING agonists, dual A2A/A2B adenosine receptors antagonist program, HPK1 inhibitors and SMARCA2 (BRM) degraders program.

Details of the e-poster presentations are as follows:

Title: In vivo and in vitro characterization of RVU330 best-in-class dual A2A/A2B adenosine receptor antagonist
Permanent Abstract Number: 5555

Title: Development of selective small molecule STING agonists suitable for systemic administration
Permanent Abstract Number: 4521A

Title: Development and characterization of small molecule HPK1 inhibitors
Permanent Abstract Number: 1947

Title: Development of novel, selective SMARCA2 (BRM) degraders for treatment of SMARCA4 (BRG1) mutated tumors
Permanent Abstract Number: 3656

The e-poster website will be launched on June 22, the first day of the AACR (Free AACR Whitepaper) Virtual Annual Meeting II. All e-posters will be made available for browsing on this date. Additional information is available at on the AACR (Free AACR Whitepaper) conference website View Source